Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01420081 · ClinicalTrials.gov registry record · Phase 2
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT01420081 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 67 participants.
The verdict
NCT01420081, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
This study will investigate the individual safety and efficacy of two dual PI3K/mTOR inhibitors in patients with recurrent endometrial cancer.
Interventions
- DRUG PF-05212384
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2012-01-19 |
| Est. Completion | 2015-12-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01420081
The ClinicalTrials.gov registry entry for NCT01420081 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-05212384 is the first listed.
NCT01420081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01420081 about?
NCT01420081 is a clinical study titled "A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer". This study will investigate the individual safety and efficacy of two dual PI3K/mTOR inhibitors in patients with recurrent endometrial cancer.
What is the current status of trial NCT01420081?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2012-01-19. Estimated completion is 2015-12-25.
What interventions are being tested in trial NCT01420081?
The interventions under investigation include: PF-05212384 (DRUG).
Who is sponsoring clinical trial NCT01420081?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.